PASI90 response: The new standard in therapeutic efficacy for psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 4, 2015, Pages 645-648

  Puig, L ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; BRODALUMAB; INFLIXIMAB; IXEKIZUMAB;

CLINICAL PRACTICE; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; DERMATOLOGY LIFE QUALITY INDEX; DESQUAMATION; DISEASE SEVERITY; ERYTHEMA; FUNCTIONAL DISEASE; HUMAN; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS AREA AND SEVERITY INDEX 90; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84925430776     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12817     Document Type: Review

References (25)

1. Bronsard V, Paul C, Prey S, et al,. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 17-22.
2. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY,. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
3. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. [WWW document] URL http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003329.pdf (last accessed: 15 August 15 2014).
4. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
5. Brown G, Malakouti M, Wang E, Koo JY, Levin E,. Anti-IL-17 phase II data for psoriasis: a review. J Dermatolog Treat 2014; Feb 20. [Epub ahead of print]
6. Puig L, Bordas X, Carrascosa JM, et al,.; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2009; 100: 277-286.
7. Katugampola RP, Lewis VJ, Finlay AY,. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007; 156: 945-950.
8. Mattei PL, Corey KC, Kimball AB,. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-337.
9. Mrowietz U,. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 2): 12-20.
10. Puig L, Carrascosa JM, Carretero G, et al,.; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013; 104: 694-709.
11. Reich K, Griffiths CE,. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008; 300: 537-544.
12. Gourraud PA, Le Gall C, Puzenat E, Aubin F, Ortonne JP, Paul CF,. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol 2012; 132: 2171-2175.
13. Mrowietz U, Kragballe K, Nast A, Reich K,. Strategies for improving the quality of care in psoriasis with the use of treatment goals-a report on an implementation meeting. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 3): 1-13.
14. Jacobson CC, Kimball AB,. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004; 151: 381-387.
15. Poulin Y, Sheth P, Gu Y, Teixeira HD,. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy. Dermatol Ther (Heidelb) 2014; 4: 33-42.
16. Navarini AA, Menter A, Teixeira HD, Gu Y, Poulin Y,. Relationship between body regions and PASI clinical components for health-related quality of life: subanalysis of REVEAL. Poster P6678. J Am Acad Dermatol 2013; 4 (Suppl. 1): AB210.
17. Herédi E, Rencz F, Balogh O, et al,. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ 2014; 15 (Suppl. 1): S111-S119.
18. Puig L, Lõpez A, Vilarrasa E, García I,. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol 2013; Aug 19. [Epub ahead of print].
19. Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M,. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20: 62-67.
20. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M,. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260-270.
21. Torii H, Sato N, Yoshinari T, Nakagawa H,; Japanese Infliximab Study Investigators. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol 2012; 39: 253-259.
22. Langley RG, Elewski BE, Lebwohl M, et al,.; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371: 326-338.
23. Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron G, Shen W, et al. A PASI ≥ 90 response is associated with improved patient reported outcomes: Results from a phase 2 study in patients with psoriasis treated with ixekizumab. P255. J Invest Dermatol 2013; 133 (S1): S43.
24. Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M,. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol 2012; 166: 797-802.
25. Rønneberg Mehren C, Clemmensen A, Boe-Hansen Dall A, Philipsen P, Gniadecki R,. Essential factors influencing health-related-quality of life in psoriasis. J Drugs Dermatol 2014; 13: 246-250.